Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial.
Del Prato S, Blonde L, Martinez L, Göke B, Woo V, Millward A, Gomis R, Canovatchel B, Strack T, Lawrence D, Freemantle N; EXPERIENCE Trial Team. Del Prato S, et al. Among authors: gomis r. Diabet Med. 2008 Jun;25(6):662-70. doi: 10.1111/j.1464-5491.2008.02438.x. Epub 2008 Apr 23. Diabet Med. 2008. PMID: 18435781 Clinical Trial.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Home PD, et al. Among authors: gomis r. Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6. Lancet. 2009. PMID: 19501900 Clinical Trial.
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.
MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ. MacDonald MR, et al. Among authors: gomis r. Diabetes Care. 2011 Jun;34(6):1394-6. doi: 10.2337/dc10-2398. Epub 2011 May 11. Diabetes Care. 2011. PMID: 21562320 Free PMC article. Clinical Trial.
Response letter to D. Singh-franco et al.
Owens DR, Del Prato S, Taskinen MR, Gomis R, Forst T, Woerle HJ. Owens DR, et al. Among authors: gomis r. Diabetes Obes Metab. 2012 Nov;14(11):1054-5. doi: 10.1111/j.1463-1326.2012.01623.x. Diabetes Obes Metab. 2012. PMID: 23034010 No abstract available.
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.
Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group. Hoogma RP, et al. Among authors: gomis r. Diabet Med. 2006 Feb;23(2):141-7. doi: 10.1111/j.1464-5491.2005.01738.x. Diabet Med. 2006. PMID: 16433711 Clinical Trial.
470 results